Could a 100-Year-Old TB vaccine help fight a tough lung infection?
NCT ID NCT07094711
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing whether the BCG vaccine, originally developed for tuberculosis, can safely treat Mycobacterium avium complex (MAC) lung disease. Researchers will give 48 adults either a single BCG injection or a placebo and monitor them for side effects, immune responses, and sputum cultures over 12 months. The goal is to see if BCG can boost the immune system to better control the infection.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- BCG vaccine (Bacillus Calmette-Guerin)
- What this could lead to
- If it works, this could point toward a new treatment option for MAC lung disease, a chronic infection that is hard to treat.
- What could go wrong
- This is a small, early-phase trial with only 48 participants. The BCG vaccine may not improve outcomes and could cause side effects like injection site reactions or flu-like symptoms.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYCOBACTERIUM AVIUM COMPLEX LUNG DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Virginia Health
RECRUITINGCharlottesville, Virginia, 22908, United States
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.